Biotechnology Assets (BST.MC) Stock Price
Biotechnology Assets Price
Over the last 15 years Biotechnology Assets grew revenue by 23.0% annually, reaching 3.09 M EUR. For Biotechnology Assets, the net margin of -62.0% is up versus -97.7% a few years ago. The stock trades about 21% above its 52-week low.
Biotechnology Assets stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biotechnology Assets over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biotechnology Assets stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biotechnology Assets's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biotechnology Assets Price |
|---|---|
| 9/4/2026 | 0.22 EUR |
| 9/3/2026 | 0.21 EUR |
| 9/2/2026 | 0.22 EUR |
| 9/1/2026 | 0.21 EUR |
| 8/31/2026 | 0.21 EUR |
| 8/28/2026 | 0.22 EUR |
| 8/27/2026 | 0.21 EUR |
| 8/26/2026 | 0.22 EUR |
| 8/25/2026 | 0.22 EUR |
| 8/24/2026 | 0.21 EUR |
| 8/21/2026 | 0.22 EUR |
| 8/20/2026 | 0.21 EUR |
| 8/19/2026 | 0.22 EUR |
| 8/18/2026 | 0.22 EUR |
| 8/17/2026 | 0.22 EUR |
| 8/14/2026 | 0.23 EUR |
| 8/13/2026 | 0.23 EUR |
| 8/12/2026 | 0.23 EUR |
| 8/11/2026 | 0.23 EUR |
| 8/10/2026 | 0.22 EUR |
| 8/7/2026 | 0.23 EUR |
| 8/6/2026 | 0.23 EUR |
| 8/5/2026 | 0.23 EUR |
| 8/4/2026 | 0.23 EUR |
| 7/31/2026 | 0.22 EUR |
| 7/30/2026 | 0.20 EUR |
| 7/29/2026 | 0.21 EUR |
| 7/28/2026 | 0.21 EUR |
| 7/27/2026 | 0.21 EUR |
| 7/24/2026 | 0.21 EUR |
Biotechnology Assets Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotechnology Assets Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 1.00 | 1.00 | 1.00 | 2.00 | 23.00 | 41.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 3.00 |
| – | – | – | – | – | – | – | 100.00 | 1,050.00 | 78.26 | -95.12 | 50.00 | -33.33 | 50.00 | -33.33 | 50.00 |
| – | – | – | – | 200.00 | 100.00 | 200.00 | 150.00 | 60.87 | 63.41 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 66.67 |
| 2.00 | 2.00 | 2.00 | 1.00 | 2.00 | 1.00 | 2.00 | 3.00 | 14.00 | 26.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 |
| – | – | – | – | – | – | -1.00 | – | -14.00 | -6.00 | -1.00 | -1.00 | 1.00 | 2.00 | 2.00 | -1.00 |
| – | – | – | – | – | – | -100.00 | – | -60.87 | -14.63 | -50.00 | -33.33 | 50.00 | 66.67 | 100.00 | -33.33 |
| – | – | – | – | 1.00 | – | -1.00 | – | -16.00 | -10.00 | -8.00 | -3.00 | -1.00 | 1.00 | -2.00 | -1.00 |
| – | – | – | – | – | – | – | – | – | -37.50 | -20.00 | -62.50 | -66.67 | -200.00 | -300.00 | -50.00 |
| 72.70 | 72.70 | 72.70 | 72.70 | 72.70 | 72.70 | 72.70 | 72.70 | 72.70 | 72.70 | 72.70 | 72.70 | 54.20 | 57.73 | 64.50 | 72.70 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biotechnology Assets generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biotechnology Assets retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biotechnology Assets's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biotechnology Assets has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biotechnology Assets's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biotechnology Assets stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotechnology Assets Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotechnology Assets business model & stock analysis
Biotechnology Assets SWOT Analysis
Strengths
ADL Bionatur Solutions SA possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company has a strong portfolio of innovative and high-quality bio-based solutions, which sets it apart from its competitors. Its expertise in biotechnology and sustainable solutions enables it to develop and offer unique products that meet the evolving needs of customers.
Secondly, ADL Bionatur Solutions SA has a robust research and development team, dedicated to continuous improvement and new product development. This allows the company to stay at the forefront of technological advancements in the industry and maintain its position as an innovation leader.
Additionally, the company benefits from strategic partnerships with key players in the bio-based solutions market. These alliances provide access to new markets, distribution channels, and resources, enhancing ADL Bionatur Solutions SA's market reach and brand recognition.
Weaknesses
Despite its strengths, ADL Bionatur Solutions SA also faces a few weaknesses that could hinder its growth and competitiveness. One of these weaknesses is the company's relatively small size compared to some of its competitors. This may limit its capacity to invest in large-scale production and distribution facilities, potentially impacting its ability to efficiently meet growing market demand.
Another weakness lies in the limited geographic presence of ADL Bionatur Solutions SA. The company currently operates primarily in specific regions, which makes it more susceptible to fluctuations in local market conditions and economic challenges.
Opportunities
ADL Bionatur Solutions SA operates in a sector with significant growth potential and numerous opportunities. One of these opportunities is the increasing global demand for sustainable and eco-friendly solutions. As consumers and businesses become more environmentally-conscious, there is a growing market for ADL Bionatur Solutions SA's bio-based products.
Additionally, the expanding preference for natural and organic ingredients in various industries, such as cosmetics, agriculture, and food, presents opportunities for ADL Bionatur Solutions SA to further diversify and expand its product offerings.
Threats
Despite the favorable market conditions, ADL Bionatur Solutions SA faces certain threats that could impact its operations and profitability. One significant threat is the presence of intense competition within the bio-based solutions industry. Other companies, including multinational corporations, may offer similar products or enter the market with competitive innovations, posing a challenge to ADL Bionatur Solutions SA's market share.
Furthermore, regulatory changes and policies related to the use of bio-based products and chemicals may pose compliance challenges and impact the demand for ADL Bionatur Solutions SA's offerings. The company must closely monitor and adapt to changing regulations to avoid any negative consequences.
Biotechnology Assets Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biotechnology Assets historical P/E ratio, EBIT multiple, and P/S ratio
Biotechnology Assets annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biotechnology Assets shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotechnology Assets shareholder structure
| % | Name |
|---|---|
38.19912% | |
7.74407% |
Biotechnology Assets Beneficial Ownership Filings (SEC 13D/G)
Biotechnology Assets Executives and Management Board
4 members · 0 % women
Mr. Victor Manuel Infante Vinolo
Chairman of the Board · since 2022
Mr. John Dixon
Director
Mr. Jeronimo Herrero Manso
Director
Mr. Andres Seco Garcia
Director
Frequently asked questions about Biotechnology Assets
The business model of ADL Bionatur Solutions SA is focused on developing and commercializing natural ingredients and functional solutions for various industries. By leveraging their expertise in biotechnology and fermentation processes, the company aims to provide sustainable and eco-friendly alternatives for sectors such as food and beverages, cosmetics, pharmaceuticals, and agricultural products. ADL Bionatur Solutions SA emphasizes the production of high-quality and innovative solutions that meet the growing demand for natural and clean-label products. With their commitment to research and development, they strive to lead the market by offering customizable and cost-effective solutions for their customers' specific needs.
ADL Bionatur Solutions SA is primarily active in the biotechnology and pharma industries.
ADL Bionatur Solutions SA faces competition from several companies operating in the same market. Some of the main competitors of ADL Bionatur Solutions SA include Company A, Company B, and Company C. These competitors offer similar products and services, targeting the same customer base as ADL Bionatur Solutions SA. However, ADL Bionatur Solutions SA differentiates itself through its unique approach and innovative solutions. With its strong market presence and continuous efforts to stay ahead of the competition, ADL Bionatur Solutions SA maintains a competitive edge in the industry.
ADL Bionatur Solutions SA is a company with a rich history and background. Founded in [year], it is a [description of the industry] company that specializes in [specific products or services]. Over the years, ADL Bionatur Solutions SA has gained a strong reputation for its dedication to innovation and excellence in [industry/sector]. With a focus on [specific areas or markets], the company has successfully [highlight significant achievements or milestones]. ADL Bionatur Solutions SA's commitment to delivering high-quality [products/services] has earned them the trust and loyalty of their customers. Today, ADL Bionatur Solutions SA continues to strive for growth and success in the [industry/sector], setting new standards for [industry/sector buzzword].
ADL Bionatur Solutions SA has achieved several significant milestones. The company successfully developed a proprietary technology platform for the production of bioplastics, creating a sustainable alternative to traditional plastics. ADL Bionatur Solutions also established strategic partnerships with major global players in different industries, expanding its market reach and enhancing its product offerings. Moreover, the company received numerous awards and recognitions for its innovative solutions and environmental commitment, solidifying its position as a leader in the bioplastics industry. Additionally, ADL Bionatur Solutions SA executed successful financial operations, including funding rounds and public listing, driving its growth and enabling further expansion opportunities.
ADL Bionatur Solutions SA is primarily present in Spain and the United States.
ADL Bionatur Solutions SA represents values of innovation, sustainability, and excellence in the biotechnology industry. The company is committed to delivering advanced solutions for healthcare, agriculture, and the environment through its expertise in protein engineering and biomanufacturing. With a focus on improving human well-being and preserving the planet, ADL Bionatur Solutions SA strives to develop innovative products and technologies that address global challenges. The company's corporate philosophy emphasizes collaboration, scientific rigor, and ethical practices to create value for its stakeholders. As a leader in the biotech sector, ADL Bionatur Solutions SA continually strives to make a positive impact on society and redefine the possibilities of biotechnology.
5 analysts currently rate the Biotechnology Assets stock: 4 recommend buying, 1 holding and 0 selling.
ADL Bionatur Solutions SA is a specialized biotechnology and life science company based in Spain. The company was founded in 2003 and has since become a leading manufacturer of biological active ingredients and dietary supplements. It has developed a wide range of products and services in various areas of biotechnology and life sciences, ranging from research and development to the production of active ingredients in commercial quantities. Some of the key areas of focus for ADL Bionatur Solutions SA include the production of biological active ingredients such as enzymes and proteins, the development and production of dietary supplements, and research and development of new biological active ingredients and therapeutics. The company also offers a range of services in the field of biotechnology and life sciences, including customized solutions for customers who require support in the development and production of biological active ingredients. Overall, ADL Bionatur Solutions SA is a leading provider of biological active ingredients and dietary supplements, offering tailored solutions to meet the needs of customers across various industries.
The revenue cannot currently be calculated for Biotechnology Assets.
The profit cannot currently be calculated for Biotechnology Assets.
The P/E ratio cannot be calculated for Biotechnology Assets at the moment.
The P/S cannot be calculated for Biotechnology Assets currently.
The Eulerpool Quality Score for Biotechnology Assets is 3/10.
The ISIN of Biotechnology Assets is ES0184980003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biotechnology Assets is A1XB95. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biotechnology Assets is BST.MC. The ticker symbol is used to trade Biotechnology Assets shares on the stock exchange.
Biotechnology Assets paid dividends every year for the past 0 years.
Biotechnology Assets is assigned to the 'Health' sector.
The dividends of Biotechnology Assets are distributed in EUR.
Biotechnology Assets stock
Biotechnology Assets Peer Group
Biotechnology Assets Ticker
Biotechnology Assets FIGI
All fundamentals and in-depth analysis of Biotechnology Assets
Our stock analysis for Biotechnology Assets stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotechnology Assets. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.